Neutrophils play a key role in host defense against invading pathogens by releasing toxic agents, such as ROS and antimicrobial peptides. Human neutrophils express several TLRs that recognize a variety of microbial motifs. The interaction between TLR and their agonists is believed to help neutrophils to recognize and to kill pathogens efficiently by increasing their activation, a process called priming. However, excessive activation can induce tissue injury and thereby, contribute to inflammatory disorders. Agonists that activate TLR7 and TLR8 induce priming of neutrophil ROS production; however, which receptor is involved in this process has not been elucidated. In this study, we show that the selective TLR8 agonist, CL075 (3M002), induced a dramatic increase of fMLF-stimulated NOX2 activation, whereas the selective TLR7 agonist, loxoribine, failed to induce any priming effect. Interestingly, CL075, but not loxoribine, induced the phosphorylation of the NOX2 cytosolic component p47phox on several serines and the phosphorylation of p38MAPK and ERK1/2. The inhibitor of p38MAPK completely blocked CL075-induced phosphorylation of p47phox Ser345. Moreover, CL075, but not loxoribine, induced the activation of the proline isomerase Pin1, and juglone, a Pin1 inhibitor, prevented CL075-mediated priming of fMLF-induced superoxide production. These results indicate that TLR8, but not TLR7, is involved in priming of human neutrophil ROS production by inducing the phosphorylation of p47phox and p38MAPK and that Pin1 is also involved in this process.
Introduction
Human neutrophils are essential for host defense against pathogens [1] [2] [3] . Neutrophils recognize pathogen-associated molecular patterns via transmembrane pattern recognition receptors, such as TLRs [4, 5] , which are transmembrane receptors that play an important role in innate immune recognition of pathogens and damaged cellderived molecules, such as triacyl lipopeptides, peptidoglycans, zymosan, lipoteichoic acid, LPS, flagellin, and demethylated CpG motifs of ssDNA [4] [5] [6] [7] . The TLR family is composed of up to 10 members in humans (TLR1-10) and 12 in mice. TLRs have a common structure with an extracellular recognition domain and an intracellular Toll/IL-1R domain. Human neutrophils express all TLR, except TLR3 [7] [8] [9] [10] . In general, TLR agonists induce an enhancement of neutrophil functions, including degranulation and the production of ROS, a process called priming [11] . TLR7 and TLR8 play an important role in initiating innate-immune responses and inflammation [9] [10] [11] [12] [13] , but the contribution of each receptor to neutrophil priming has not been elucidated.
TLR7 and TLR8 are phylogenetically and structurally related [4] [5] [6] and are located in the endosomes. Whereas viral ssRNA is the natural ligand of TLR7 and TLR8, several compounds have been synthetized and specifically recognize TLR7/8. These include R848 (imidazoquinoline resiquimod, which is a potent agonist of TLR7/8) [6, 14] or CL097 (a highly water-soluble derivative of R848, which also acts on TLR7/8) [13, 15] . In addition, CL075 (3M002) more specifically recognizes TLR8 [16] whereas loxoribine is more specific for TLR7 [17] . It has been shown that TLR7/8 agonists induce neuroinflammation and skin inflammation [15, 18] ; however, their effect on neutrophil inflammatory functions has not been fully elucidated. We [13] and others [9, 12] have shown that R848 and CL097 induce priming of neutrophil ROS production and lipid mediator biosynthesis. Moreover, CL097 induces p47phox phosphorylation on selective sites (Ser345, -328, and -315) and Pin1 activation in human neutrophils [13] .
The enzyme responsible for neutrophil ROS production is the NOX2 [19] [20] [21] . The NOX2 consists of a membrane-bound flavocytochrome b558 (composed of p22phox and gp91phox/ NOX2) and 4 cytosolic proteins: p47phox, p67phox, p40phox, and Rac1/2 [19] [20] [21] . In unactivated cells, the subunits are segregated in the membranes and cytosol. Stimulation of cells by various agonists induces the phosphorylation of p47phox and activation of the NOX2 [22] , which is accompanied by the migration of p47phox, together with the other cytosolic components, to the membrane where they associate with the flavocytochrome b558 to assemble the catalytically active oxidase [23] [24] [25] . Agonists, such as the bacterial peptide fMLF and the pharmacological PKC activator PMA at micromolar concentrations, strongly induce p47phox phosphorylation on several serines and NOX2 activation [22, 26] . Proinflammatory agents, such as cytokines (GM-CSF, TNF-a, LPS), induce a very weak oxidative response by neutrophils but strongly enhance ROS release upon exposure to a secondary stimulus, such as fMLF [11] . This priming effect could facilitate the rapid elimination of the pathogen at the infection site [11, 27] ; however, excessive and uncontrolled priming could participate in the inflammatory reaction and thus, be selfdestructive [11, 28] . The priming effect has been shown to result in partial phosphorylation of p47phox [29] [30] [31] [32] [33] , Pin1 activation [13, 34] , and translocation to the plasma membrane of the flavocytochrome b588 located in granules [29, 35] .
In this study, we used more selective agonists for TLR7 and TLR8 to investigate the role of each receptor in the priming of neutrophil ROS production. The data show that the TLR8-selective agonist was able to induce priming of NOX2 activation, p47phox phosphorylation, and Pin1 activation, indicating that TLR8, and not TRL7, is involved in the priming process.
MATERIALS AND METHODS

Reagents
CL097, CL075, and loxoribine were from InvivoGen (San Diego, CA, USA). fMLF, cytochrome c, protease and phosphatase inhibitors, endotoxin-free buffers, and salt solutions were from Sigma Chemical (St. Louis, MO, USA). SDS-PAGE and Western blotting reagents were purchased from Bio-Rad Laboratories (Hercules, CA, USA). The rabbit polyclonal antibodies against p47phox and the phospho sites of p47phox have been described elsewhere [26, 36] .
Neutrophil preparation
Circulating neutrophils were isolated from healthy volunteer whole blood by Polymorphprep (Axis Shield, Dundee, Scotland) gradient centrifugation [36, 37] . The neutrophil band was collected, and the cells were washed in PBS and counted. Neutrophils were 96% pure and 99% viable.
Superoxide anion production assay
Neutrophils were treated with CL097, CL075, or loxoribine at 37°C for 30 min in HBSS. Cytochrome c (1 mg/ml) was added, and extracellular superoxide anion production was measured in response to fMLF by detecting the SODinhibitable reduction of ferricytochrome c at 550 nm, every 20 s for 10 min, by use of a Uvikon spectrophotometer [32, 37] . The initial rate of production of superoxide was calculated by use of the 5 1st points of the curve and an extinction coefficient of 21.1 mM 21 cm
21
.
RNA extraction and PCR
Neutrophils were isolated as described above, and monocytes were isolated as described previously [38] . 
Western blotting analysis
Neutrophils (15310 6 ) in HBSS (400 ml) were treated with CL097, CL075, or loxoribine for the indicated times and at the indicated concentrations at 37°C with mild shaking. The reaction was stopped by adding 53 concentrated Laemmli sample buffer [39] containing 5 mM Na 3 VO 4 , 2.5 mM para-nitrophenyl phosphate, 10 mM NaF, 5 mM/L EDTA, 5 mM/L EGTA, 20 mg/ml leupeptin, 20 mg/ml pepstatin, and 20 mg/ml aprotinin [33] . Samples were then incubated for 2 min in boiling water (100°C) and stored at 280°C until use. Neutrophil lysates were sonicated and subjected to 10% SDS-PAGE (equivalent of 1 3 10 6 cells/well)
by use of standard techniques [36] . The separated proteins were transferred to nitrocellulose, which was blocked with 5% milk in TBST for 1 h [36, 40] . After blocking, the membranes were probed with the appropriate antibody, i.e., antiphospho-Ser315-p47phox (1:2000), anti-phospho-Ser328-p47phox (1:2000), antiphospho-Ser345-p47phox (1:10,000), anti-p47phox (1:5000), anti-phosphop38MAPK(Thr180/Tyr182; 1:1000), and anti-phospho-ERK1(T202/204)/ERK2 (T185/Y187; 1:2000), followed by incubation with HRP-labeled goat anti-rabbit antibody (1:5000). The protein bands were revealed by use of luminol reagent (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Pin1 activity assay
Pin1 activity was measured by use of a previously described technique with some modifications [13, 34] . In brief, neutrophils were lysed by succinct sonication (twice for 10 s at 4°C) in lysis buffer containing 50 mM HEPES, 100 mM NaCl, 0.25% CHAPS, 5 mM NaF, 1 mM b-glycerophosphate, and 1 mM EGTA. The assay mixture consisted of 93 ml HEPES buffer (50 mM HEPES, pH 7.8, 100 mM NaCl, 2 mM DTT, 0.04 mg/ml BSA), 5 ml cell lysate (equivalent of 10 5 cells), and 2 ml (20 mg/ml) trypsin solution (Sigma Chemical). The reaction was started by adding 50 ml (720 mM) of the peptide Trp-Phe-Tyr-Ser(PO 3 H 2 )-ProArg-pNA (NeoMPS, France), and the p-nitroaniline released was followed continuously for 4 min by spectrophotometry at 390 nm.
Statistical analysis
All results are expressed as means 6 SEM. Significant differences (P , 0.05) were identified by the Student's t-test and by 1-way ANOVA, followed by Tukey's post hoc test by use of GraphPad software (version 4.0; GraphPad Software, La Jolla, CA, USA).
RESULTS
Effect of CL075 and loxoribine on fMLF-induced superoxide anion production
We [13] and others [9] have previously shown that agonists activating TLR7 and TLR8, such as R848 and CL097, induce the priming of neutrophil ROS production; however, it is still unclear whether TLR7 and/or -8 are involved in this response. To address this question, we tested the effect of CL075, a selective TLR8 agonist, and loxoribine, a selective TLR7 agonist ( Fig. 1) , on neutrophil superoxide production by use of the SODinhibitable cytochrome c reduction assay. As expected, the results showed that CL097 induced enhancement of fMLF-induced superoxide anion production ( Fig. 2A) . Interestingly, CL075 also induced enhancement of fMLF-induced superoxide anion production, whereas loxoribine had no effect. Treatment of cells with CL075 and loxoribine resulted in a superoxide anion production similar to that of CL075 alone. The priming effect of CL075 on superoxide anion production was similar to that of CL097 ( Fig. 2B and C) , as both agonists induced a concentrationdependent priming with a peak at 2.5 mg/ml. In contrast, loxoribine did not induce any significant priming at all concentrations tested (Fig. 2D) . Interestingly, fMLF alone induced a concentration-dependent superoxide production; however, whereas the response to fMLF after treatment with CL075 plateaued between 10 27 and 10 25 M, the priming effect (i.e., comparing 6CL075) was the highest at 10 27 M fMLF (Supplemental data). These results suggest that TLR8, but not TLR7, is involved in the priming of fMLF-induced neutrophil superoxide anion production.
Human neutrophils express more TLR8 than TLR7
With the use of Western blotting and commercial antibodies, we have previously shown that the TLR7 and TLR8 proteins are present in human neutrophils [13] ; however, the expression level of each receptor has not been evaluated so far. Therefore, we used PCR to determine the expression level of TLR7 and TLR8. We compared TLR7 and TLR8 mRNA levels by use of specific primers for each receptor and used TLR4 and human monocytes as positive controls. The data show that human neutrophils express TLR4, TLR7, and TLR8 mRNA (Fig. 3) . However, the level of TLR7 mRNA was lower than that of TLR8 or TLR4 mRNA. In contrast, human monocytes expressed the same levels of TLR7 and TLR8 mRNA.
Effect of CL075 and loxoribine on p47phox phosphorylation in human neutrophils
The priming of neutrophil ROS production induced by inflammatory agents, such as TNF-a and the TLR7/8 agonist Figure 1 . Structure and properties of TLR7 and TLR8 agonists. CL097 (imidasoquinoline; derivative R848) is a TLR7/8 common agonist. CL075 (3M002; thiazoloquinolone) is a specific TLR8 agonist, and loxoribine (imiquimode derivative; a small antiviral synthetic molecule) is a specific TLR7 agonist. The 3 ligands are small, synthetic molecules that are soluble in water. CL097, is associated with the phosphorylation of p47phox [13, 33] . Thus, we then tested whether CL075 and loxoribine induced activation of these pathways by use of Western blotting and specific antibodies directed against the phosphorylated sites of these proteins. As expected, CL097 alone induced the phosphorylation of p47phox on Ser345, -328, and -315 (Fig. 4) . Interestingly, CL075 induced the phosphorylation of p47phox on the same sites (Ser345, -328, and -315), whereas loxoribine alone had no or little effect.
Effect of CL075 and loxoribine on MAPK phosphorylation in human neutrophils and implication on p47phox phosphorylation
As p47phox-Ser345 is known to be phosphorylated by MAPKs [33] , and the TLR7/8 agonist CL097 induces ERK1/2 and p38 MAPK phosphorylation [13] , we studied further the effect of TLR7-and TLR8-selective agonists on these pathways. Western blot analysis showed that incubation of human neutrophils with CL075 alone induced ERK1/2 and p38MAPK phosphorylation (Fig. 5A) , whereas loxoribine only induced a weak ERK1/2 and p38MAPK phosphorylation. To identify the MAPK involved in CL075-induced Ser345 phosphorylation, we tested the effect of SB203580 and PD98059, inhibitors of p38MAPK and the ERK1/2 pathway, respectively. SB203580 completely inhibited the phosphorylation of p47phox Ser345 (Fig. 5B) , whereas PD98059 had only a weak effect. GF109203X, a PKC inhibitor, had no effect on Ser345 phosphorylation. Altogether, these results suggest that TLR8, but not TLR7, activates ERK1/2 and p38 MAPK but that only p38MAPK is involved in CL075-induced phosphorylation of p47phox on Ser345.
CL075 induces activation of Pin1, which is necessary for CL075-induced priming
We have previously shown that TNF-a-and CL097-induced NOX2 priming in human neutrophils involves the activation of Pin1 and that Pin1 mediates NOX2 hyperactivation by binding to p47phox-phosphorylated Ser345 [13, 34] . Thus, we tested the role of Pin1 in CL075-induced NOX2 priming. Our results show that the TLR8-selective agonist induced Pin1 activation, which was similar to that induced by CL097, and that this activity was inhibited by juglone, a selective Pin1 inhibitor (Fig. 6A) . In contrast, loxoribine had no effect on Pin1 activity. Interestingly, juglone inhibited the CL075-induced priming of the NOX2 activation in a concentration-dependent manner (Fig. 6B) .
These results indicate that TLR8, but not TLR7, is involved in Pin1 activation in human neutrophils and that Pin1 controls CL075-induced NOX2 hyperactivation.
DISCUSSION
Human neutrophils express several TLRs that recognize a variety of microbial motifs and chemical agonists. The interaction between TLRs and their agonists is believed to facilitate the detection and elimination of pathogens by neutrophils. However, excessive neutrophil activation can induce tissue injury that is believed to participate in inflammatory reactions. Thus, it is important to understand the effects of TLR agonists on neutrophil functions and the pathways involved in these Figure 3 . Expression of TLR4, TLR7, and TLR8 mRNA in human neutrophils and monocytes. Total RNA was extracted from neutrophils and monocytes by use of standard techniques. mRNA levels for TLR4, TLR7, and TLR8 were determined by PCR by use of specific primers. GAPDH was used as loading control and buffer as negative control. The size of the products is represented in base pairs (bp). Figure 4 . Effect of CL097, CL075, and loxoribine on p47phox phosphorylation in human neutrophils. Neutrophils (15 3 10 6 cells/ml) were treated, with CL097 (5 mg/ml), CL075 (5 mg/ml), or loxoribine (10 mg/ml) for 30 min at 37°C. The cells were lysed, and proteins were denatured and analyzed by SDS-PAGE and Western blotting with p47phox anti-phospho-Ser345 (P-S345), anti-phospho-Ser328 (P-S328), and anti-phospho-Ser315 (P-S315) antibodies or anti-p47phox (p47 processes. The TLR7/8 agonists R848 and CL097 have been shown to induce the priming of neutrophil ROS production. Here, we show that CL075, a selective TLR8 agonist, induced priming of NOX2 activation, whereas loxoribine, a selective TLR7 agonist, did not. This work identifies TLR8 as the main receptor responsible for neutrophil priming.
Human neutrophils express mRNA for all TLR, except TLR3 [7] [8] [9] . Indeed, we detected TLR7 and TLR8 mRNA in human neutrophils; however, the level of TLR7 mRNA was lower than that of TLR8 mRNA. Our results are in agreement with other studies showing that TLR7 mRNA is 5-to 10-fold less expressed than TLR8 mRNA [9, 41] . In contrast, it has been shown that the protein levels of TLR7 and TLR8 are comparable in human neutrophils, as detected by commercial antibodies [13] . This difference between the mRNA and protein levels of TLR7 could be a result of the fact that neutrophils are short-lived cells with low mRNA levels but with "ready-to-use" proteins in their subcellular compartments.
In our previous study [13] , we had shown that CL097, which activates both TLR7 and TLR8, did not stimulate NOX2 activation in human neutrophils but induced a dramatic increase of superoxide production after fMLF stimulation. In addition, CL097 induced cytochrome b558 translocation to the plasma membrane; phosphorylation of the NOX2 cytosolic component p47phox on Ser345, Ser328, and Ser315; and Pin1 activation. In the current study, we tested the effect of CL075 [16] and loxoribine [17] to understand better the contribution of each receptor to the priming of the NOX2. It has been shown that CL075 (also named 3M002) did not activate HEK293 cells transfected with human TLR7 but induced activation of cells expressing human TLR8 [16] , whereas loxoribine induced the activation of HEK293 cells transfected with human TLR7 but had no effect on cells expressing human TLR8 [17] . Here, we show that CL075 induces the priming of superoxide anion production in a manner comparable with the priming induced by CL097, whereas loxoribine had not effect. CL075 alone did not induce superoxide production by neutrophils (data not shown). The effects of CL075 and loxoribine were confirmed by use of a luminol-amplified chemiluminescence assay, and similar results were obtained (data not shown). We sought to determine if CL075 and loxoribine were able to trigger pathways involved in neutrophil NOX2 hyperactivation, such as p47phox phosphorylation and MAPK and Pin1 activation. Indeed, CL075 induced ERK1/2 and p38MAPK phosphorylation and the significant phosphorylation of p47phox on serine 345, 328, and 315 that was lost with the use of the p38MAPK inhibitor, pointing to the involvement of the p38MAPK pathway. Although ERK1/2 were activated, their role in the phosphorylation of p47phox on Ser345 appeared minimal. Loxoribine had little to no effect on these pathways. CL075 induced Pin1 activation that was similar to that obtained by CL097, whereas loxoribine had no effect. The Pin1 inhibitor juglone inhibited CL075-induced neutrophil priming. Altogether, these results show that TLR8 is able to trigger signaling pathways involved in NOX2 hyperactivation in human neutrophils and suggest that TLR8, but not TLR7, is responsible for NOX2 priming and activation of signaling pathways observed after treatment with CL097 and other TLR7/8 agonists in human neutrophils. Our results support the data reported by Janke et al. [42] , showing that the TLR8 agonist, but not the TLR7 agonist, was able to induce neutrophil degranulation. However, data from the literature show that loxoribine can induce autophagy and related signaling pathways in human neutrophils, suggesting that TLR7 plays a role in specific neutrophil functions [43] .
The natural ligands for TLR8 are identified as ssRNA, released by internalized viruses in the endosomal compartment [4, 5] . The phagolysosome is a highly acidic environment that contains several enzymes that can damage viral particles, leading to ssRNA release and recognition by TLR8. This receptor is expressed in endosomal membranes and is able to recognize regions rich in guanosine and uridine, HIV-1, vesicular stomatitis virus, and influenza viruses. Therefore, TLR8, but not TLR7, could participate in virus-induced inflammatory processes and could be targeted to inhibit this process.
In conclusion, we have shown herein that the selective activation of TLR8 leads to enhanced NOX2-derived ROS production in human neutrophils. TLR8 is able to trigger signaling cascades leading to p47phox phosphorylation and Pin1 activation. Therefore, we here suggest that specific targeting of TLR8 could be a novel anti-inflammatory approach in viral infections.
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